Precision Biosciences vs Spero Therapeutics
Spero Therapeutics is the larger business, with $66.8m of revenue in fiscal 2025 against $34.3m for Precision Biosciences (1.9 times as much). Spero Therapeutics grew faster (39.2% against -50.1%). Spero Therapeutics kept more of each dollar of sales as profit: a net margin of 12.8% against -133.4%. Precision Biosciences carries less debt relative to equity (0.0% against 0.2%).
| Latest fiscal year | Precision BiosciencesDTIL, 2025 | Spero TherapeuticsSPRO, 2025 |
|---|---|---|
| Revenue | $34.3m | $66.8m |
| Revenue growth | -50.1% | 39.2% |
| Net income | −$45.7m | $8.6m |
| Operating margin | -152.2% | 9.5% |
| Net margin | -133.4% | 12.8% |
| Return on equity | -61.5% | 16.3% |
| Free cash flow | −$65.9m | −$12.6m |
| Cash | $111m | $40.3m |
| Total debt | $0 | $91,000 |
| Debt to equity | 0.0% | 0.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 68 | 25 |
| Market value | $192m | $60.8m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 6 buys, 11 sales | 0 buys, 9 sales |